Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 11:17 PM ET

Pharmaceuticals

Company Overview of Actavis Pharma, Inc.

Company Overview

Actavis Pharma, Inc. develops, manufactures, and markets generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. The company was formerly known as Schein Pharmaceutical, Inc. The company was founded in 1931 and is based in Parsippany, New Jersey. As of August 28, 2000, Actavis Pharma, Inc. operates as a subsidiary of Allergan plc.

Morris Corporate Center III

400 Interpace Parkway

Parsippany, NJ 07054

United States

Founded in 1931

1,325 Employees

Key Executives for Actavis Pharma, Inc.

Senior Vice President of Strategic Development
Age: 62
Senior Vice President of Technical Operations
Age: 69
Other Professional
Age: 66
Other Professional
Other Professional
Age: 73
Compensation as of Fiscal Year 2015.

Actavis Pharma, Inc. Key Developments

Actavis Pharma, Inc. Wins $28.09 Million Federal Contract

Actavis Pharma Inc. has won a $28,088,035.50 federal contract modification from the U.S. Department of Veterans Affairs, Hines, Illinois, for clonidine patches.

Cipher Pharmaceuticals Inc., Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. Enters into Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc

Cipher Pharmaceuticals Inc. along with its partners, Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. have entered into a settlement agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules). As part of the settlement agreement, Cipher, Ranbaxy and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the U.S. on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Orexigen Therapeutics, Inc. and Takeda Pharmaceuticals File Lawsuit against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc. and Actavis Inc. For Infringement of Contrave Patents

Orexigen Therapeutics, Inc. announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Contrave (naltrexone HCl /bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Takeda and Orexigen filed the lawsuit on the basis that Actavis' proposed generic products infringe each of these patents.

Similar Private Companies By Industry

Company Name Region
Matrix Laboratories Inc. United States
Improve USA, Inc. United States
Immune Response BioPharma, Inc. United States
Amalyte Pharmaceuticals, LLC United States
Pure Distributors, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Actavis Pharma, Inc., please visit www.actavis.com/en/Global+Business/Generics/default.htm. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.